Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research
-
J. Bone Miner. Res. · Dec 2007
Randomized Controlled Trial Multicenter StudyTwo-year treatment with denosumab (AMG 162) in a randomized phase 2 study of postmenopausal women with low BMD.
Denosumab is a monoclonal antibody to RANKL. In this randomized, placebo-controlled study of 412 postmenopausal women with low BMD, subcutaneous denosumab given every 3 or 6 mo was well tolerated, increased BMD, and decreased bone resorption markers for up to 24 mo. Continued study of denosumab is warranted in the treatment of low BMD in postmenopausal women. ⋯ In these postmenopausal women with low BMD, treatment with denosumab for 2 yr was associated with sustained increases in BMD and reductions in bone resorption markers compared with placebo.
-
J. Bone Miner. Res. · Dec 2007
Multicenter Study Comparative StudyComparisons of body size, composition, and whole body bone mass between North American and South African children.
We compared whole body BMC of 811 black, white, and mixed ancestral origin children from Detroit, MI; Johannesburg, South Africa; and Cape Town, South Africa. Our findings support the role of genetic and environmental influences in the determination of bone mass in prepubertal children. ⋯ WBBMC is lower in children of European ancestry compared with African ancestry, irrespective of geographical location; however, South African children have significantly higher WBBMC compared with USB and USW groups, thereby acknowledging the possible contribution of environmental factors. Reasons for the significantly higher WBBMC in the children of mixed ancestral origin compared with the other groups need to be studied further.